ストックスクリーナーアプリを入手
253.06
2.79%
6.86
アフターアワーズ：
253.06
前日終値:
$246.20
開ける：
$245.41
24時間の取引高:
1.72M
Relative Volume:
1.39
時価総額：
$35.59B
収益：
$5.54B
当期純損益:
$1.52B
株価収益率:
24.40
EPS:
10.3734
ネットキャッシュフロー:
$1.74B
1週間 パフォーマンス:
+4.47%
1か月 パフォーマンス:
+14.01%
6か月 パフォーマンス:
+13.97%
1年 パフォーマンス:
-5.04%
1日の値動き範囲:
$244.18
$253.62
1週間の範囲:
$235.50
$253.62
52週間の値動き範囲:
$180.26
$277.67
Resmed Inc Stock (RMD) Company Profile
Compare RMD vs ISRG, BDX, ALC, MDLN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
253.06 | 35.59B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
443.85 | 156.80B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
200.42 | 54.59B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
70.63 | 34.14B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.88 | 30.60B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-08-19 | 開始されました | Rothschild & Co Redburn | Neutral |
| 2026-07-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-07-13 | ダウングレード | Citigroup | Buy → Neutral |
| 2026-06-17 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2026-04-15 | 開始されました | JP Morgan | Overweight |
| 2025-12-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | 開始されました | Citigroup | Buy |
| 2025-09-02 | アップグレード | CLSA | Hold → Outperform |
| 2025-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 開始されました | Morgan Stanley | Overweight |
| 2025-01-16 | 開始されました | Goldman | Buy |
| 2025-01-10 | 開始されました | Piper Sandler | Neutral |
| 2024-12-13 | 開始されました | Stifel | Hold |
| 2024-09-24 | 開始されました | Robert W. Baird | Outperform |
| 2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | ダウングレード | Needham | Buy → Hold |
| 2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | アップグレード | Needham | Hold → Buy |
| 2023-09-05 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 開始されました | UBS | Buy |
| 2023-04-14 | 開始されました | Mizuho | Buy |
| 2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
| 2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
| 2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
| 2022-01-31 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-01-13 | アップグレード | CLSA | Outperform → Buy |
| 2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
| 2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
| 2021-08-02 | ダウングレード | Needham | Buy → Hold |
| 2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
| 2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
| 2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-06-22 | 開始されました | Robert W. Baird | Neutral |
| 2021-06-21 | 繰り返されました | Needham | Buy |
| 2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-09 | アップグレード | CLSA | Sell → Outperform |
| 2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-16 | アップグレード | Needham | Hold → Buy |
| 2020-11-02 | アップグレード | UBS | Neutral → Buy |
| 2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 開始されました | CLSA | Underperform |
| 2020-01-31 | ダウングレード | UBS | Buy → Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Perform |
| 2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | アップグレード | UBS | Neutral → Buy |
| 2019-07-16 | ダウングレード | UBS | Buy → Neutral |
| 2019-05-06 | アップグレード | UBS | Neutral → Buy |
| 2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
ResMed back to Hold - www.intelligentinvestor.com.au
Goodman, Pro Medicus and ResMed FY26 Results: Growth Drivers and FY27 Outlook - Kalkine
Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.
ResMed Inc. (NYSE:RMD) Stock Now Rated "Hold" by Sell-Side Analysts - MarketBeat
ResMed Inc. (ASX:RMD): Operations, Earnings and Business Priorities - Kalkine
Resmed Launches AirTouch F40 Full Face Fabric CPAP Mask in US - HomeCare
ETFs Are Net Sellers of ResMed (RMD) on Oct. 16 - Yahoo Finance
Resmed Inc (ASX:RMD) Expands Sleep Therapy Portfolio Following Fiscal Results - Kalkine
What Does ResMed’s (ASX:RMD) Latest Annual Report Mean for Investors? - Kalkine
ResMed to Launch AirTouch F40 Sleep Apnea Mask - marketscreener.com
Resmed, Inc. Launches AirTouch F40 Full Face Fabric CPAP Mask In The US - www.marketscreener.com
Form 4 ResMed Inc: Aaron Bloomer (CFO) For: 14 August By Investing.com - Investing.com South Africa
A fabric sleep apnea mask is designed to fit 96% of people. Resmed says it will be available in the U.S. Oct. 28. - Stock Titan
Form 4 ResMed Inc: Aaron Bloomer (CFO) For: 14 August By Investing.com - Investing.com UK
Form 4 ResMed Inc: Justin Leong (Chief Product Officer) For: 14 August - Investing.com UK
ResMed Inc. (RMD) Stock Forecasts - Yahoo! Finance Canada
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
ResMed Inc. (RMD) Stock Forecasts - Yahoo! Finance Canada
ResMed (NYSE:RMD) Share Price Crosses Above 50 Day Moving AverageShould You Sell? - MarketBeat
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed’s Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
Mizuho Adjusts Price Target on ResMed to $240 From $235 - www.marketscreener.com
EBITDA of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA - TradingView
ResMed Q4 2026 Earnings Call Transcript - Benzinga
Is ResMed Facing Fresh Questions Before Results (ASX:RMD)? - Kalkine Media
Form 144 RESMED INC For: 10 October By Investing.com - Investing.com South Africa
Form 144 RESMED INC For: 10 October By Investing.com - Investing.com Nigeria
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Form 4 ResMed Inc For: 8 October By Investing.com - Investing.com Nigeria
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance Singapore
ResMed (NYSE:RMD) Stock: Insider Michael Farrell Sells 4,991 Shares - MarketBeat
ResMed chairman & CEO Michael Farrell sells $1.1m in shares - Investing.com
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
What Is Shaping Breville, Treasury Wine and ResMed? - Kalkine Media
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Michael Farrell proposes selling 4,991 ResMed (NYSE: RMD) shares through Fidelity. - Stock Titan
ResMed (NYSE:RMD) Offers Dividend Investors a Sustainable Payout Built on Quality Fundamentals - ChartMill
ResMed plans USD 1.5 billion share repurchase and RBC raises target for ResMed stock - ad-hoc-news.de
Resmed (ASX:RMD) Shares Slide Over the Year Even as Record Q4 Revenue and a Higher Dividend Close Fiscal 2026 - Kalkine
ResMed stock pre-market at EUR 199.20: plus 0.48 percent - ad-hoc-news.de
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
ResMed Inc Reports CDI and Common Stock Movements for September 2026 - Kalkine
RSMDF | RESMED INC ORD Insider Trading - Quiver Quantitative
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Stifel reiterates Hold on ResMed stock amid market share concerns - Investing.com
ResMed Inc. $RMD Shares Sold by Envestnet Asset Management Inc. - MarketBeat
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
Resmed Inc (RMD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO |
Oct 07 '26 |
Sale |
226.33 |
4,991 |
1,129,637 |
479,803 |
| Farrell Michael J. | Officer |
Oct 07 '26 |
Proposed Sale |
226.33 |
4,991 |
1,129,638 |
0 |
| Farrell Michael J. | Officer |
Sep 08 '26 |
Proposed Sale |
226.22 |
4,991 |
1,129,064 |
0 |
| Farrell Michael J. | Chairman and CEO |
Sep 08 '26 |
Sale |
222.44 |
4,991 |
1,110,191 |
466,256 |
| Farrell Michael J. | Chairman and CEO |
Sep 08 '26 |
Option Exercise |
146.34 |
4,991 |
730,383 |
471,247 |
| FARRELL PETER C | Director |
Sep 02 '26 |
Sale |
234.73 |
970 |
227,688 |
51,803 |
| Peter C Farrell | Director |
Sep 02 '26 |
Proposed Sale |
234.65 |
970 |
227,608 |
0 |
| Farrell Michael J. | Chairman and CEO |
Aug 07 '26 |
Option Exercise |
146.34 |
4,991 |
730,383 |
471,247 |
| Farrell Michael J. | Chairman and CEO |
Aug 07 '26 |
Sale |
205.69 |
4,991 |
1,026,596 |
466,256 |
| Farrell Michael J. | Officer |
Aug 07 '26 |
Proposed Sale |
205.69 |
4,991 |
1,026,596 |
0 |
4.75%
1.22%
大文字化:
|
ボリューム (24 時間):